All In Biotech

Drug Trial Radar · NCT07210047

Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients

A Phase Ib/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Efficacy of HuL001 in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

21

Planned (sponsor's estimate)

Start

Aug 18, 2025

Primary completion

Nov 30, 2027

Study completion Jan 31, 2028

Sponsor

Lead sponsor
HuniLife Biotechnology, Inc.Industry
Sponsor type
Industry
First posted
Oct 7, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if the antibody drug HuL001, combined with Lenalidomide/Dexamethasone works to treat Multiple Myeloma patients. It will also learn about the safety and tolerability of the therapeutic combination. The objectives of this study are: 1. To evaluate the safety and tolerability of HuL001 (in combination with Len/Dex). 2. To evaluate the efficacy of HuL001 (in combination with Len/Dex). Researchers will use the antibody drug HuL001, combined with Len/Dex, to see if this works for Multiple Myeloma therapy. Participants will: * Receive HuL001 antibody injections every 2 weeks * Take Lenalidomide for 21 consecutive days each month * Take Dexamethasone every 1 week * Visit the clinic on scheduled days for checkups and tests * Keep a diary of their symptoms and Myeloma responses.

Conditions

  • Multiple Myeloma Refractory

Interventions

  • HuL001Drug

    Anti-ENO1 monoclonal antibody

  • Lenalidomide/DexamethasoneDrug

    Lenalidomide in combination with dexamethasone is indicated for the treatment of adult patients with multiple myeloma (MM)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Myeloma responses, including sCR, CR, VGPR, PR, MR, SD, PD, clinical relapse, ORR, CBR, DoR, time to sCR, time to CR, time to VGPR, time to PR, time to MR, as assessed by the investigator according to the IMWG criteria.Time frame: From enrollment to the end of treatment at 8 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Far Eastern Memorial Hospital

    Taipei, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.